Artios Pharma
Health
· Headquartered in United Kingdom 🇬🇧
Track Artios Pharma
— get Health deals in free daily digest
Overview
Artios Pharma, a Cambridge-based biopharmaceutical company founded in 2016, raised $115 million in a Series D financing round co-led by SV Health Investors and RA Capital Management. The company focuses on developing cancer medicines targeting DNA damage response pathways, with its lead program, alnodesertib, showing a 50% confirmed overall response rate in patients with ATM-negative solid tumors. Artios is valued at $765 million.
Products
Loading...
Synthesising company profile
Reading press coverage to extract founders, customers, traction signals and competitive positioning…
Recent Announcements
Investors: SV Health Investors, RA Capital Management
Artios Pharma, a Cambridge-based biopharmaceutical company founded in 2016, raised $115 million in a Series D financing round co-led by SV Health Investors and RA Capital Management. The company focuses on developing cancer medicines targeting DNA damage response pathways, with its lead program, alnodesertib, showing a 50% confirmed overall response rate in patients with ATM-negative solid tumors. Artios is valued at $765 million.
More Health Deals
Market Map
View thousands of companies by category in our market map:
